Your session is about to expire
← Back to Search
Anti-tumor antibiotic, Anti-metabolites
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase 2
Waitlist Available
Led By Karen Seiter, MD
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Approved for 10 Other Conditions
All Individual Drugs Already Approved
Summary
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.
Eligible Conditions
- Burkitt Lymphoma
- Lymphoblastic Lymphoma
- Leukemia
- Acute Lymphoblastic Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CLAG-MExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
New York Medical CollegeLead Sponsor
71 Previous Clinical Trials
6,104 Total Patients Enrolled
Karen Seiter, MDPrincipal InvestigatorNew York Medical College
1 Previous Clinical Trials
100 Total Patients Enrolled